Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.
about
Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer ActivitiesThe domain landscape of virus-host interactomesCDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.Cyclin-dependent kinase 9 inhibition protects cartilage from the catabolic effects of proinflammatory cytokinesCyclin-dependent kinase 9 may as a novel target in downregulating the atherosclerosis inflammation (Review).BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cellsCDK9 and its repressor LARP7 modulate cardiomyocyte proliferation and response to injury in the zebrafish heartSerum cyclin-dependent kinase 9 is a potential biomarker of atherosclerotic inflammation.Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to Suppress Melanoma.Down-regulating cyclin-dependent kinase 9 of alloreactive CD4+ T cells prolongs allograft survival.Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.Ready, pause, go: regulation of RNA polymerase II pausing and release by cellular signaling pathwaysOverview of CDK9 as a target in cancer research.SIRT7-dependent deacetylation of CDK9 activates RNA polymerase II transcriptionRecent advances in the identification of Tat-mediated transactivation inhibitors: progressing toward a functional cure of HIV.Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents.Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).MicroRNA-874 inhibits cell proliferation and induces apoptosis in human breast cancer by targeting CDK9.The emerging picture of CDK9/P-TEFb: more than 20 years of advances since PITALRE.Computer-aided design, synthesis and validation of 2-phenylquinazolinone fragments as CDK9 inhibitors with anti-HIV-1 Tat-mediated transcription activity.Targeting of CDK9 with indirubin 3'-monoxime safely and durably reduces HIV viremia in chronically infected humanized mice.Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9.Identification of novel inhibitors against Cyclin Dependent Kinase 9/Cyclin T1 complex as: Anti cancer agent.Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs.Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.Computational study and peptide inhibitors design for the CDK9 - cyclin T1 complex.Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer.Glucocorticoid-induced phosphorylation by CDK9 modulates the coactivator functions of transcriptional cofactor GRIP1 in macrophages.The emerging roles of CDK12 in tumorigenesis.In vitro and in vivo anti-tumor and anti-inflammatory capabilities of the novel GSK3 and CKD9 inhibitor ABC1183.MicroRNA-613 inhibits the progression of gastric cancer by targeting CDK9.MicroRNA-874 inhibits cell proliferation and invasion by targeting cyclin-dependent kinase 9 in osteosarcoma.Molecular principle of the cyclin-dependent kinase selectivity of 4-(thiazol-5-yl)-2-(phenylamino) pyrimidine-5-carbonitrile derivatives revealed by molecular modeling studies.Transcriptional targeting of oncogene addiction in medullary thyroid cancer
P2860
Q27675842-0DE6F892-5890-4E71-B556-FF972FC40AD2Q33786731-7DEEDDDC-E169-4091-896E-5AD43BA661A7Q33864755-371EDC58-6F18-4E1E-89E9-8E3D7A51FC9BQ34022536-A9C66263-26BC-4EBD-831D-DFF5C44C41C8Q34265421-02F6704C-7420-4FA1-9A8A-CC7BDE02C536Q35574955-86C92296-9B16-4FC1-A059-1F6B210AD40AQ35834044-834775EE-BE7B-4629-BF2B-583D18E31498Q36738991-D3A2B26A-BB95-48A8-A363-13AB99F468C1Q36811094-A7A4A930-2135-4DD6-BFAC-EDDD084531F9Q37295249-A158C1C0-EEC7-4616-8090-C00C25A92274Q37399378-DB797D8B-A4A3-48DB-9311-4E1D67EEA3FDQ38562823-DDF838D0-B239-483E-922A-E2C924499244Q38696353-429C35B0-C8DF-4FCB-9E68-8ED3393FD249Q38706788-00FA381F-C6B0-4052-BCAC-DAFDBEDE8335Q38757713-4E8ACD8B-1264-4831-B3E7-5C0127DBC903Q38806786-9DDBE960-8931-4F04-84FF-AF900AE6A214Q38949247-0110D0FB-E728-4797-A0D3-8D9B6BC7B504Q38950635-65A0F979-48E0-4F36-8DF5-3704643EDBFBQ39005055-323CC933-FFB9-4330-A24A-4B70AA7968CCQ39073158-2FC1C548-EE53-4AC5-833A-FB929DDDECB3Q40079572-F1FA4BD6-2C7E-4497-B5DB-6857BE68551DQ41292799-58D4A78C-38A1-4686-9568-24EDEEC8C485Q41457054-8A39317A-183C-48C9-88EE-96B41B533FBEQ41869723-109EF7E4-0447-45E9-BA7A-92BB640684F2Q41963512-7AB91103-C25C-4024-9C54-8840E3B7B61DQ45741706-9CFAAADD-D05C-4B63-AACD-2F1E02572A3CQ46420204-C8CB8ABC-43F1-4832-A67F-B79DA1B3CEC0Q47144286-A38DF89B-7F82-4413-B882-FC72E0A1AC35Q47155353-5B2177B2-14B9-47CC-BFF4-6C1BA7DE3FEAQ50056226-C8347695-9CB3-4B9C-8338-AACB80892113Q53166772-276091C1-9F9E-4C73-AC9E-D1DFDF259644Q54112430-53A8DD42-941B-491F-AEF9-E86B942CA17DQ55033883-AB76E5BA-8E53-47B8-8D43-DD38FE0C6476Q58710816-920B7A10-9CBF-4A9F-89EF-6F89761BA3F2
P2860
Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.
@en
type
label
Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.
@en
prefLabel
Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.
@en
P2860
P921
P1476
Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target
@en
P2093
Robert Fürst
Sonja Baumli
P2860
P304
P356
10.2174/138161212800672750
P577
2012-01-01T00:00:00Z